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Malaria  is  one  of  the most  important  parasitic  diseases  of  man.  The  development  of drug  resistance  in
malaria  parasites  is an  inevitable  consequence  of  their  widespread  and  often  unregulated  use.  There  is
an urgent  need  for new  and  effective  drugs.  Pyronaridine  is a known  antimalarial  drug  that  has  received
renewed  interest  as  a partner  drug  in  artemisinin-based  combination  therapy.  To  study  its  pharmacoki-
netic  properties,  particularly  in  ﬁeld  settings,  it is necessary  to develop  and  validate  a robust,  highly
sensitive  and  accurate  bioanalytical  method  for drug  measurements  in  biological  samples.  We have
developed  a sensitive  quantiﬁcation  method  that covers  a wide  range  of  clinically  relevant  concentra-
tions  (1.5  ng/mL  to 882  ng/mL)  using  a relatively  low  volume  sample  of  100  L  of whole  blood.  Total  run
time  is  5 min  and  precision  is within  ±15%  at all concentration  levels.  Pyronaridine  was  extracted  on  a
weak  cation  exchange  solid-phase  column  (SPE)  and  separated  on  a HALO  RP  amide  fused-core  columnioanalysis using  a  gradient  mobile  phase  of  acetonitrile–ammonium  formate  and  acetonitrile-methanol.  Detection
was  performed  using  electrospray  ionization  and  tandem  mass  spectrometry  (positive  ion  mode  with
selected  reaction  monitoring).  The  developed  method  is  suitable  for implementation  in high-throughput
routine  drug  analysis,  and  was used  to  quantify  pyronaridine  accurately  for up  to 42  days  after  a  single
oral  dose  in a drug-drug  interaction  study  in  healthy  volunteers.
© 2017  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Introduction
Malaria is one of the most important infectious diseases in the
orld, resulting in an estimated 214 million cases and 438,000
eaths in 2015 [1]. Children under the age of ﬁve bear the main
urden of malaria-attributed deaths. Artemisinin-based combina-
ion therapy (ACT) is the World Health Organization recommended
rst-line treatment against P. falciparum malaria [2]. The fast-
cting artemisinin component kills the majority of parasites during
he ﬁrst days of treatment. As, this class of drug has a short
iological half-life [3,4], it is necessary to combine it with a long-
cting partner drug to eliminate residual parasites and ensure cure.
∗ Corresponding author at: Mahidol-Oxford Tropical Medicine Research Unit, Fac-
lty  of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand.
E-mail address: danielb@tropmedres.ac (D. Blessborn).
1 Current address: Department of Chemistry, University of Warwick, Coventry,
K.
ttp://dx.doi.org/10.1016/j.jpba.2017.08.023
731-7085/© 2017 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
Pyronaridine is a synthetic antimalarial drug, developed in the
1970s, which has been used as a mono-therapy in China. It has
a long biological half-life (13–17 days) and is therefore suitable to
use in ACTs [5–7]. The ﬁxed-dose combination of artesunate and
pyronaridine is a newly developed and deployed ACT, which has
shown excellent efﬁcacy against both P. falciparum and P. vivax
malaria [8].
Sensitive and accurate bioanalytical methods are crucial for
high-quality pharmacokinetic studies. There are a few methods
published for the quantiﬁcation of pyronaridine in plasma [9–12],
and most of these require a sample volume of 200–250 L of plasma
and present a quantitation limit of 10 ng/mL or higher [11,12].
Hodel et al. reported a LC–MS/MS method able to quantify pyronar-
idine at 1 ng/mL [10], but the run time was  reported to be over
20 min  making it unsuitable for high throughput routine analy-
sis of clinical studies. An in vivo study in rabbits showed a high
blood-to-plasma distribution ratio (4.9-17.8) for pyronaridine [13],
suggesting that whole blood rather than plasma would be the
preferred sample matrix for drug measurements [6,14]. Several
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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8Fig. 1. Chemical structure 
uantiﬁcation methods have been reported for whole blood, but
ith a relatively poor sensitivity (i.e. 20–30 ng/mL) [13,15,16]. A
ecent LC–MS/MS method [17] used a sample volume of 300 L,
esulting in a lower limit of quantiﬁcation (LLOQ) of 5.7 ng/mL.
owever, liquid-liquid extraction was employed which is labo-
ious and difﬁcult to automate. Another crucial drawback in the
reviously reported LC–MS/MS methods is that none of them used
table isotope-labeled internal standards, and could therefore be
ompromised by matrix effects.
The aim of this work was to develop a sensitive and accurate
uantiﬁcation method of pyronaridine in low volume whole blood
amples that is suitable for implementation into high-throughput
outine drug quantiﬁcation in clinical trials.
. Materials and methods
.1. Materials
Pyronaridine tetraphosphate (Fig. 1) and its stable isotope
abeled internal standard, pyronaridine-13C2D4 (SIL-PYN), was
rovided by the Worldwide Antimalarial Resistance Network Ref-
rence program [18]. LC–MS grade of water, acetonitrile and
ethanol were obtained from JT Baker (Phillipsburg, USA). All
ther chemicals and reagents were of analytical grade. Formic
cid (98%), ammonium formate and ammonium carbonate were
rom Sigma–Aldrich (St. Louis, USA). Acetic acid was obtained
rom Merck (Darmstadt, Germany). Blank blood in ﬂuoride-oxalate,
DTA, Na-heparin, Li-heparin, and ﬂuoride-heparin was collected
rom healthy volunteers at the Faculty of Tropical Medicine, Mahi-
ol University, Thailand.
.2. Sample preparation
.2.1. Preparation of standards and working solution
Stock solutions (1 mg/mL) of pyronaridine and SIL-PYN were
repared in methanol-formic acid 1% (50:50 v/v) and stored in
ethanol-washed cryo vials at −80 ◦C. Working solutions were
repared in human plasma-water (50:50 v/v) and used for spiking
f whole blood. All solutions were allowed to equilibrate to room
emperature before use.
.2.2. Preparation of calibrators and quality control samples
Fresh ﬂuoride-oxalate whole blood was used to prepare cal-
bration standards at a concentration range of 1.47–882 ng/mL
nd LLOQ at 1.47 ng/mL, upper limit of quantiﬁcation (ULOQ) at
82 ng/mL and over-curve samples (OC) at 1807 ng/mL. Qualityonaridine tetraphosphate.
control (QC) samples at 4.67, 57.2 and 452 ng/mL were prepared
from a second stock solution. The ﬁnal volume of working solution
in whole blood was less than 5% in all samples.
2.2.3. Extraction procedure
Sample preparation and SPE was  performed on a Freedom Evo
200 platform (TECAN, Mannedorf, Switzerland). Pipette tips, 96-
well plates and seal mats were all methanol-washed before use.
Whole blood samples (100 L) were manually aliquoted to the 96-
well plate. Then, by liquid handler, 100 L plasma-water 50:50 v/v
was added in the ﬁrst well (i.e. double blank) and 100 L of inter-
nal standard (30 ng/mL) in plasma-water 50:50 v/v was  added to
all other wells. Four hundred microliters of ammonium carbon-
ate (20 mM,  pH 8.8) was added to all wells and then covered with
a seal mat. The 96-well plate was mixed for 2 min at 1000 rpm
and centrifuged for 2 min  at 1100 × g. Then 500 L of the cen-
trifuged sample was  transferred to a 96 well plate solid phase
CBA extraction plate (Biotage, Uppsala, Sweden) and extracted
according to the following procedure; (1) conditioning of the SPE
cartridge with 1 mL  methanol followed by 1 mL  ammonium car-
bonate (20 mM,  pH 8.8), (2) loading of the whole blood sample
(500 L), (3) washing with 1 mL  ammonium carbonate (20 mM,  pH
8.8) followed by 1.5 mL  methanol-ammonium carbonate 20 mM
(80:20 v/v) and ﬁnally 1 mL  methanol-water (50:50 v/v), (4) elu-
tion with 0.9 mL  methanol-formic acid (98:2 v/v). The eluates were
evaporated under a gentle stream of nitrogen at 70 ◦C (Caliper
TurboVap
®
96) until dryness and reconstituted in 400 L mobile
phase A (see below section 2.3.1). The extracted and reconstituted
samples were mixed for 2 min  at 1000 rpm, centrifuged for 2 min
at 1100 × g and placed in the autosampler to equilibrate for at least
30 min  before analysis.
2.3. Instrumentation and chromatographic conditions
2.3.1. Chromatography
The LC system was an Agilent 1260 inﬁnity system consisting of
a binary LC pump, a vacuum degasser, a temperature-controlled
micro-well plate autosampler set at 4 ◦C and a temperature-
controlled column compartment set at 40 ◦C (Agilent technologies,
CA, USA). Data acquisition and processing were performed using
Analyst 1.5.2 (Applied Biosystems/MDS Sciex, CA, USA). The
compounds were analyzed on a Halo amide fused-core column
(50 mm × 2.1 mm;  I.D. 2.7 m)  with a Halo amide pre-column
(5 mm  × 2.1 mm;  I.D. 2.7 m)  at a ﬂow rate of 400 L/min
(Advanced Materials Technology, Wilmington, DE, USA). The
mobile phase consisted of solvent A: acetonitrile–ammonium for-
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ate (10 mM with 1% formic acid) (10:90 v/v) and solvent B:
cetonitrile–methanol (25:75 v/v). The mobile phase gradient was
: 0–1.5 min, B: 1.7–2.9 min  and A: 3.1–5.0 min  (with 0.2 min  gra-
ient switch) and total run-time of 5 min. The sample injection
olume was 2 L.
.3.2. Mass spectrometry
An API 5000 triple quadrupole mass spectrometer (Applied
iosystems/MDS Sciex) with TurboV ionization source interface
perating in the positive ion mode was used for the MS/MS  analysis.
on spray voltage was set to 5500 V, with a drying temperature at
50 ◦C. The curtain gas was 30 psi and the nebulizer (GS1) and aux-
liary (GS2) gases 45 and 55 psi, respectively. Quantiﬁcation was
erformed using selected reaction monitoring for the transitions
/z  518.10–447.15 and 524.25–453.15 (collision energy of 23 V)
or pyronaridine and SIL-PYN, respectively.
.4. Validation
The assay was validated according to the US Food and Drug
dministration (FDA) guidelines on bioanalytical method valida-
ion [19]. Accuracy and precision of the method was  determined
y analysis of 5 replicate sets of 5 concentrations (1.47, 4.67, 57.2,
52 and 882 ng/mL) analyzed in 4 separate runs. The ability to
ilute over-curve samples was investigated at 1807 ng/mL and
:4 dilution with blank blood. Overall accuracy was calculated as
he mean of the relative accuracies (i.e. relative error compared
o the nominal concentration) at each QC level. Precision of the
ethod (within-run, between-run and total-variability) was cal-
ulated using analysis of variance (ANOVA) and expressed as the
elative standard deviation (%RSD).
.4.1. Linearity, selectivity and recovery
Linearity was assessed using the calibration standards from the
our separate runs. The most suitable regression model was chosen
ased on the accuracy of the back-calculated concentrations of the
alibration curves and QC samples [20].
Selectivity was evaluated by analysis of six blank samples
rom six different blood donors, and using different antico-
gulants (ﬂuoride-oxalate, EDTA, Na-heparin, Li-heparin and
uoride-heparin). Potentially interfering antimalarial drugs (i.e.
hloroquine, amodiaquine, artesunate, dihydroartemisinin, pri-
aquine and piperaquine) were evaluated using post-column
nfusion and also a conventional LC run.
Recovery was determined by comparing the peak area of QC
amples ( × 5 at each level) with that of extracted blank blood sam-
les post-spiked to contain the same nominal concentration as the
C sample, simulating a 100% extraction recovery.
.4.2. Matrix effect and carry-over
Post-column infusion was performed with injection of blank
xtracted blood samples from six different donors. Blood from a
ingle donor was also collected with different anticoagulants to
valuate potential matrix effects from the different anticoagulants.
o calculate the matrix effect, the MS  response from extracted blank
amples (post-spiked) was  divided with the MS  response of the
nalyte in neat solution, at the same nominal concentration. A cal-
ulated matrix effect below 0.85 or above 1.15 would imply that a
atrix effect was  present. Carry-over effects were also investigated
y injecting 3 blank samples (mobile phase) directly after ﬁve injec-
ions of extracted samples at the ULOQ. If the signal was more than
0% of that of LLOQ it would be classiﬁed as carry-over effects..4.3. Stability
Stability of pyronaridine in whole blood was investigated dur-
ng 3 freeze/thaw cycles where samples were frozen at −80 ◦C Biomedical Analysis 146 (2017) 214–219
and then thawed at room temperature for 2–3 h during each 24 h
freeze/thaw cycle. Short term stability at room temperature (22 ◦C)
and at 4 ◦C was investigated at 4 h, 24 h and 48 h. Long-term stabil-
ity at −80 ◦C for 1 year for both spiked samples and stock solutions
were evaluated. Stability was also investigated during different
steps in the extraction process e.g. buffer pre-treated blood (before
SPE extraction) 4 h at 22 ◦C, extracted samples (in elution solution)
at 4 ◦C for 24 h, as evaporated samples stored at 4 ◦C for up to 72 h
as well as stability in LC autosampler at 4 ◦C for up to 72 h. A heat
deactivating test was  evaluated at 60 ◦C for 1 h to inactivate any
HIV viruses in the blood samples [21–23].
2.5. Clinical pharmacokinetic study with incurred sample
reanalysis
This assay was  used to quantify pyronaridine in whole blood
samples as part of an open-label cross-over study (NCT01552330)
to evaluate the potential pharmacokinetic drug-drug interactions
between pyronaridine-artesunate and primaquine in 17 healthy
Thai volunteers [5]. The drug was  given as a single oral dose of
artesunate-pyronaridine (Pyramax
®
, Shin Poong Pharmaceuticals,
Republic of Korea), with and without primaquine (Thai Govern-
ment Pharmaceutical Organization [Thai GPO], Bangkok, Thailand).
Blood samples were collected at different time intervals until day
42. A total of 680 samples were analyzed. A total of 73 samples were
selected for incurred sample reanalysis.
3. Results and discussion
The range of the calibration curve 1.47–882 ng/mL was  based
on published clinical pharmacokinetic patient data [14,17] with an
extended range to cover between-patient differences. In the drug-
drug interaction study in healthy volunteers [5], ﬂuoride-oxalate
was used as an anticoagulant for all drugs in the study and this
anticoagulant was  therefore selected for the validation of pyronar-
idine.
Pyronaridine adsorbs readily to different surface materials, par-
ticularly to glass but also to some extent to plastic surfaces. This
is a major problem when diluting stock solutions with water at
low concentrations, affecting working solutions and internal stan-
dards which could lead to seriously biased results if not taken into
consideration [24–26]. The adsorption issue was eliminated in the
developed method by using diluted plasma for both working solu-
tions and internal standard dilutions.
3.1. Sample preparation
It is important that the spiked samples, which are used to quan-
tify the unknown clinical samples, mimic  the study samples as
closely as possible. A shift in pH or too much organic solvent
may  precipitate some of the blood components. Plasma-water
(50:50 v/v) was  used to prepare the working solutions from a stock
solution containing methanol-formic acid 1%. The amount of stock
solution added was  kept low (<5%) to avoid any precipitation of
plasma in the dilution step. The generated plasma-water working
solution would then have minimal effect on the spiked whole blood.
For sample extraction, protein precipitation is quick and easy
but it also releases many other components from the blood
sample, potentially contaminating the detector and causing the
LC–MS/MS system to suffer from matrix effects. Liquid-liquid
extraction has been used in many previous methods for pyronari-
dine [9,11,13,16,17] but it can be complicated and laborious when
running large number of clinical study samples. SPE with a weak
cation exchange extraction column is the selective method produc-
ing a clean extract; this extraction method is fast and suitable for
D. Blessborn et al. / Journal of Pharmaceutical and Biomedical Analysis 146 (2017) 214–219 217
Table  1
Accuracy and precision when quantifying pyronaridine in whole blood.
Sample Concentration (ng/mL) Within-run precision (%) Between–run precision (%) Total-run precision (%) Accuracy (%)
LLOQ 1.47 9.83 14.8 10.9 1.45
QC  1 4.67 7.23 8.42 7.44 −1.87
QC  2 57.2 4.56 9.27 5.57 −0.38
QC  3 452 3.93 2.56 3.74 3.36
ULOQ 882 3.26 4.38 3.46 −3.27
OC  (1:4) 1807 3.64 4.53 3.80 −0.89
Results are presented from the analysis of 5 replicates/day over 4 days at each concentration level, using spiked ﬂuoride-oxalate whole blood samples. Within-, between- and
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t  each QC level. Precision and accuracy must be within ±15% for all control levels e
igh throughput analysis when operated in the 96 well plate for-
at. The SPE washing consisted of three steps; (1) buffer only to
ash out remaining blood components before (2) a high methanol
ash step and ﬁnally (3) water-methanol to wash out remaining
uffer before adding the elution solvent. This generated a very clean
xtract suitable for LC–MS/MS analysis, thus preventing down time
f the instrument.
.2. Instrumentation and chromatographic conditions
It was challenging to ﬁnd a suitable LC-column for pyronaridine
hat produced a symmetrical peak shape. In the published litera-
ure, most LC-UV methods used ion-pairing reagents to improve
he peak shape, but this is often not compatible with MS-detection
27]. Most C18 and CN columns that were screened showed various
egrees of peak tailing, but a good peak shape was  obtained from
he amide fused-core HALO column without using any additives.
he MS  was operated in the positive ion mode, which gener-
ted several abundant fragment ions of pyronaridine (518.1 m/z);
47.2 m/z, 376.2, 378.2 and 341.2 m/z  (listed in decreasing order of
bundance).
.3. Validation
The assay was validated according to the US FDA guidelines
n bioanalytical method validation. Accuracy and precision of
he method was determined by ANOVA and the method showed
atisfactory performance (RSD below 15% at all concentration lev-
ls) when quantifying pyronaridine-spiked ﬂuoride-oxalate whole
lood samples (Table 1).
.3.1. Linearity, selectivity and recovery
Different calibration models were evaluated. The simplest
odel that described the calibration curve adequately and returned
igh accuracy for back-calculated QC samples was  ordinary lin-
ar regression with 1/x weighting. The developed method showed
ood selectivity with no interfering peaks when analyzing blank
lood from six different donors and also when using different
nticoagulants (ﬂuoride-oxalate, EDTA, Na-heparin, Li-heparin and
uoride-heparin). Furthermore, injection of high concentrations of
ommonly used antimalarial drugs (i.e. chloroquine, amodiaquine,
rtesunate, dihydroartemisinin, primaquine and piperaquine)
id not interfere with the quantiﬁcation of pyronaridine (data
ot shown). Recoveries (extracted sample/post-extraction spiked
ample) were in the range of 65–75% for pyronaridine in ﬂuoride-
xalate whole blood, similar to that previously reported [13,15–17].
.3.2. Matrix effect and carry-over
Matrix effect investigation with post-column infusion did not
how any increase or decrease of the pyronaridine signal when
njecting extracted blank blood from 6 different donors or when
sing different anticoagulants. Matrix effects were also inves-f the relative accuracies (i.e. relative error compared to the nominal concentration)
 at LLOQ which should be within ±20%.
tigated by extracting blank blood that was post-spiked and
comparing the response with spiked neat solution. The calculations
showed a post-spiked/spiked neat solution ratio close to 1 for all
samples, proving no ion suppression or enhancement from any of
the 6 different blood donors or from the different anticoagulants.
Carry-over was noted after 150–250 samples (Fig. 2) and could
not be eliminated with a more potent needle wash solution or
longer wash time. The injector used a ﬂow through design that
should theoretically eliminate potential carry-over effects. How-
ever, the carry-over originated from contamination of the injection
needle tip, and to solve this problem, a custom cleaning program
was implemented between sample injections. The injection needle
aspirated and dispensed a washing solution 4 times from each of
the 4 wash-vials before aspirating the sample, followed by standard
needle wash in a ﬂush port for 15 s with acetonitrile-water-acetic
acid (70:29:1 v/v/v) and injection of the sample onto the column.
The 4 wash-vials contained the following solutions; Vial 1: acetoni-
trile:methanol 25:75; Vial 2: acetonitrile-formic acid (2% in water)
50:50 v/v; Vial 3: water only; Vial 4: mobile phase A. This cus-
tom wash successfully removed the carry-over problems but added
almost 1 min  to the run time of each sample.
3.3.3. Stability
Freeze/thaw stability over three cycles showed good stability for
spiked QC samples in ﬂuoride-oxalate and EDTA. Fluoride-heparin
barely passed the stability criteria, while Na-heparin and Li-heparin
resulted in a 10–15% loss in each freeze-thaw cycle resulting in
a total loss of 40–50% after three freeze-thaw cycles. There were
no visual differences (precipitation or clogging) between cycles or
samples that would explain such a signiﬁcant drop. Thus, due to the
poor freeze-thaw performance, Na-heparin and Li-heparin should
not be used as anticoagulants for measurement of pyronaridine in
blood samples.
Short term stability for up to 48 h in ﬂuoride-oxalate blood
at 22 ◦C and at 4 ◦C showed good stability without any degrada-
tion of the analyte. Long-term stability at −80 ◦C in the different
anticoagulants showed good stability for up to 6 months. At 12
months the QC3 level was still within the 15% limit, but almost
all measurements at the QC1 level were just outside the 15% limit
(Table 2). However, after 50 months ﬂuoride-oxalate samples are
still within the acceptable range indicating some of the drop at 12
months could have been inﬂuenced by variation in the prepara-
tion of the fresh standards. Unfortunately no other anticoagulant
samples were left for analysis at that time.
The stability of spiked ﬂuoride-oxalate blood samples in the
extraction process, i.e. buffer pre-treated blood waiting for extrac-
tion for up to 4 h at 22 ◦C, extracted samples in elution solution
stored at 4 ◦C for up to 24 h, evaporated samples stored at 4 ◦C for
up to 72 h, all showed acceptable stability proﬁles. The stability in
the LC injector at 4 ◦C for up to 72 h and the heat deactivation at
60 ◦C for 1 h also showed good stability without any degradation
of pyronaridine. The evaluated heat deactivation cannot deactivate
218 D. Blessborn et al. / Journal of Pharmaceutical and Biomedical Analysis 146 (2017) 214–219
Fig. 2. Overlay of blank human ﬂuoride-oxalate blood and pyronaridine (1.47 ng/mL) with internal standard (SIL-PYN; 30 ng/mL) showing early signs of carry-over in the
blank  sample after about 80 sample injections.
Table 2
Long-term stability of pyronaridine at −80 ◦C.
Fluoride oxalate EDTA Li-heparin Na-heparin Fluoride-heparin
QC 1 QC 3 QC 1 QC 3 QC 1 QC 3 QC 1 QC 3 QC  1 QC 3
Day  0 100 100 100 100 100 100 100 100 100 100
2  months 106 101 107 103 100 103 99 104 101 105
6  months 89 95 96 100 98 99 89 99 92 93
12  months 83 97 89 97 84 87 80 86 81 92
50  months 89 90 N/A N/A N/A N/A N/A N/A N/A N/A
T ntrol samples were measured using this calibration curve, therefore all values has been
n  are presented as percentages. Concentration level of QC 1 is 4.67 ng/mL and QC  3 is
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nhe calibration curve was  prepared in ﬂuoride-oxalate. All other anticoagulant co
ormalized vs day 0 QC concentration measurements for each anticoagulant and
52  ng/mL. N/A, Not available.
ll types of viruses but it will deactivate HIV viruses and hopefully
educe most other viruses making bioanalysis safer for laboratory
orkers [21–23]. Both pyronaridine and SIL-PYN stock solutions
howed good stability when stored at −80 ◦C for up to 12 months.
.4. Clinical applicability of the developed method
The developed and validated method was used to analyze a
harmacokinetic study in 17 healthy Thai volunteers [5]. Frequent
lood samples were collected for up to 42 days after a single
ral dose to evaluate the potential drug-drug interaction between
rtesunate-pyronaridine and primaquine. The developed method
as implemented in a high-throughput setting, capable of ana-
yzing up to 300 samples per day. The method showed excellent
linical applicability, covered the therapeutic range of observed
oncentrations, and was able to quantify clinical samples accurately
ith high sensitivity. Total precision (%CV) of quality control sam-
les during analysis were 3.53%, 4.16% and 4.20% for QC1, QC2 and
C3. All day 42 samples (n = 31) were above the LLOQ concentration
evel. A concentration-time proﬁle for a single healthy volunteer
s shown in Fig. 3. A maximum concentration of 464 ng/mL was
eached after 1 h and the drug was eliminated from the body with
n elimination half-life of 17 days, resulting in a total exposure
AUC) of 11,100 (hr × ng/mL) in whole blood. Similar pharmacoki-
etic proﬁles could be seen for all volunteers.Fig. 3. Observed concentration–time proﬁle of pyronaridine after a single oral dose
of  3 Pyramax® tablets (180 mg pyronaridine tetra-phosphate and 60 mg artesunate
per tablet) was given to a healthy adult Thai volunteer.
To further test the reproducibility of the method, incurred sam-
ple reanalysis was performed on 73 out of 680 samples and the
results were compared with the original data from the study. All
samples were within the ±20% deviation limit and met  the accep-
tance criteria for incurred sample reanalysis, proving a reproducible
method free from any analytical issues.
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adsorption to plastic containers and retention of drugs in cultured cells under
in vitro conditions, Eur. J. Pharm. Biopharm. 64 (2006) 369–378.
[27] C.R. Mallet, Z. Lu, J.R. Mazzeo, A study of ion suppression effects in
electrospray ionization from mobile phase additives and solid-phase extracts,
Rapid Commun. Mass Spectrom. 18 (2004) 49–58.D. Blessborn et al. / Journal of Pharmaceuti
. Conclusions
The analytical method for pyronaridine in ﬂuoride-oxalate
hole blood passed the FDA validation criteria successfully and
howed excellent accuracy and precision. The new method had
uch shorter run time (5 min) compared to previously published
ethods and used only 100 L of whole blood. It provided a
ower quantiﬁcation limit of 1.5 ng/mL. However, there were a
ew ﬁndings that need to be highlighted. To avoid adsorption of
yronaridine or internal standard to surfaces, all working solu-
ions used for dilution needed to contain a small volume of
iluted plasma. Fluoride-oxalate and EDTA showed good freeze-
haw stability but Li-heparin and Na-heparin should be avoided
ue to the decreased recovery with subsequent freeze-thaw cycles.
arry-over issues in the HPLC-autosampler were overcome with
he developed custom cleaning program that was implemented
etween sample injections.
Whole blood samples from a healthy volunteer study showed
hat the calibration curve covered the whole concentration range
rom the study subjects and that the method could quantify
yronaridine for up to 42 days after a single oral dose. The smaller
ample volume of 100 L compared to previously published meth-
ds will be a signiﬁcant advantage in future ﬁeld pharmacokinetic
tudies, particularly in the study of young children.
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